Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW. Francis DP, et al. Among authors: gorse gj. AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31. AIDS Res Hum Retroviruses. 1998. PMID: 9814961 Review.
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, et al. Graham BS, et al. Among authors: gorse gj. J Infect Dis. 1994 Oct;170(4):782-6. doi: 10.1093/infdis/170.4.782. J Infect Dis. 1994. PMID: 7930718 Clinical Trial.
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al. Graham BS, et al. Among authors: gorse gj. J Infect Dis. 1993 Mar;167(3):533-7. doi: 10.1093/infdis/167.3.533. J Infect Dis. 1993. PMID: 8095059 Clinical Trial.
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. Mascola JR, et al. Among authors: gorse gj. J Infect Dis. 1996 Feb;173(2):340-8. doi: 10.1093/infdis/173.2.340. J Infect Dis. 1996. PMID: 8568294 Clinical Trial.
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE. Graham BS, et al. Among authors: gorse gj. J Infect Dis. 1998 Feb;177(2):310-9. doi: 10.1086/514209. J Infect Dis. 1998. PMID: 9466516 Clinical Trial.
110 results